Dr. Matthew Pavao

Cooley advised Degron Therapeutics on intellectual property due diligence matters in connection with its $1.2 billion collaboration agreement with Takeda Pharmaceuticals. Degron and Takeda will collaborate to utilize Degron’s GlueXplorer platform to identify, validate and optimize molecular glue degraders for specific therapeutic targets selected by Takeda.

Cooley advised Autolus – a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies – on its strategic collaboration with BioNTech, an immunotherapy company pioneering novel therapies for cancer and other serious diseases, to advance both companies’ autologous CAR-T programs toward commercialization, as well as a $350 million underwritten offering.

Cooley advised Tectonic Therapeutic, a privately held biotechnology company developing G-protein coupled receptor-targeted therapeutic proteins, on its definitive merger agreement to combine in an all-stock transaction with AVROBIO, a gene therapy company with a purpose to free people from a lifetime of genetic disease. Tectonic also obtained $130.7 million in private financing commitments with a syndicate of new and existing leading life sciences investors in connection with the merger.

Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering.

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its strategic collaboration with Moderna.